1.Therapy for hepatorenal syndrome.
Chinese Journal of Hepatology 2003;11(10):627-627
3.Current treatments for hepatorenal syndrome.
Su LIU ; Wei-xin HE ; Wei-fen XIE
Chinese Journal of Hepatology 2003;11(10):638-640
4.Treatment of septic shock in children with low dose pituitrin: report of 24 cases.
Zi-jiang YANG ; Jing-feng LI ; Li-min FU ; Shang-bing LEI ; Jun-hua LIU ; Yong WU ; Yan-ping HU
Chinese Journal of Pediatrics 2011;49(11):858-861
OBJECTIVETo explore the clinical effect of low dose pituitrin in children with septic shock.
METHODSA total of 48 pediatric cases with septic shock, in whom 6 hours, conventional treatment could not reverse shock from January 2008 to December 2010, were selected for this study. The patients were divided into two groups randomly (completely random design) (control group 24, remedial group 24). The conventional treatment included antibiotics/fluid resuscitation/correcting acid-base imbalance, glucocorticoid, organ (heart/lung) support, dopamine 1 - 15 µg/(kg·min) and norepinephrine 0.5 - 2 µg/(kg·min) pumped in continuously in the control group. In initial 6 hours the same treatment was given to the remedial group, while low dose pituitrin (0.01 - 0.03 U/min) was pumped additionally during the rest of time. The therapeutic effect on correcting shock was evaluated in both groups.
RESULTSThe total effective rate was 76.2% in the remedial group and 40.0% in the control group; the mortality was 33.3% and 60% respectively. The difference between both groups was significant (P = 0.025).
CONCLUSIONLow dose pituitrin could improve the clinical effect significantly in children with septic shock in whom 6 hours conventional treatment failed to correct shock, shorten the total periods of treatment, and decrease mortality.
Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Norepinephrine ; therapeutic use ; Pituitary Hormones, Posterior ; administration & dosage ; therapeutic use ; Shock, Septic ; drug therapy ; Treatment Outcome ; Vasoconstrictor Agents ; therapeutic use
5.Extensive variability in vasoactive agent therapy: a nationwide survey in Chinese intensive care units.
Xian-Bo PEI ; Peng-Lin MA ; Jian-Guo LI ; Zhao-Hui DU ; Qing ZHOU ; Zhang-Hong LU ; Luo YUN ; Bo HU
Chinese Medical Journal 2015;128(8):1014-1020
BACKGROUNDInconsistencies in the use of the vasoactive agent therapy to treat shock are found in previous studies. A descriptive study was proposed to investigate current use of vasoactive agents for patients with shock in Chinese intensive care settings.
METHODSA nationwide survey of physicians was conducted from August 17 to December 30, 2012. Physicians were asked to complete a questionnaire which focused on the selection of vasoactive agents, management in the use of vasopressor/inotropic therapy, monitoring protocols when using these agents, and demographic characteristics.
RESULTSThe response rate was 65.1% with physicians returning 586 valid questionnaires. Norepinephrine was the first choice of a vasopressor used to treat septic shock by 70.8% of respondents; 73.4% of respondents favored dopamine for hypovolemic shock; and 68.3% of respondents preferred dopamine for cardiogenic shock. Dobutamine was selected by 84.1%, 64.5%, and 60.6% of respondents for septic, hypovolemic, and cardiogenic shock, respectively. Vasodilator agents were prescribed by physicians in the management of cardiogenic shock (67.1%) rather than for septic (32.3%) and hypovolemic shock (6.5%). A significant number of physicians working in teaching hospitals were using vasoactive agents in an appropriate manner when compared to physicians in nonteaching hospitals.
CONCLUSIONSVasoactive agent use for treatment of shock is inconsistent according to self-report by Chinese intensive care physicians; however, the variation in use depends upon the form of shock being treated and the type of hospital; thus, corresponding educational programs about vasoactive agent use for shock management should be considered.
Data Collection ; Dobutamine ; therapeutic use ; Dopamine ; therapeutic use ; Humans ; Intensive Care Units ; statistics & numerical data ; Norepinephrine ; therapeutic use ; Shock ; drug therapy ; Shock, Cardiogenic ; drug therapy ; Shock, Septic ; drug therapy ; Surveys and Questionnaires ; Vasoconstrictor Agents ; therapeutic use ; Vasodilator Agents ; therapeutic use
6.Treatment Update on Portal Hypertension and Complications.
The Korean Journal of Gastroenterology 2010;56(3):144-154
Current understanding of the pathophysiology of portal hypertension has resulted in therapeutic approaches aimed at correcting the increased splanchnic blood flow and some of which have been already used in clinical practice. Recently new perspectives opened and erstwhile paradigm has been changed to focus on increased resistance to portal blood flow and the formation of portosystemic collateralization. Several studies revealed the clear-cut mechanisms of hepatic endothelial dysfunction and abnormal angiogenesis contributing to the development of portal hypertension. Thus the modulations of hyperdynamic circulation or angiogenesis seem to be valuable therapeutic targets. In the current review update, we discuss the multidisciplinary management of modulating hepatic vascular resistance and abnormal angiogenesis associated with portal hypertension. However, these new pharmacological approaches are still under investigation and widescale clinical application are needed to develop effective strategies.
Adrenergic beta-Antagonists/therapeutic use
;
Bone Marrow Transplantation
;
Cyclooxygenase Inhibitors/therapeutic use
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
;
Hypertension, Portal/*therapy
;
Neovascularization, Pathologic/drug therapy
;
Nitric Oxide/metabolism
;
Vascular Resistance
;
Vasoconstrictor Agents/therapeutic use
7.Guidelines for the Treatment of Functional Dyspepsia.
Sam Ryong JEE ; Hye Kyung JUNG ; Byung Hoon MIN ; Kee Don CHOI ; Poong Lyul RHEE ; Young Woo KANG ; Sang In LEE
The Korean Journal of Gastroenterology 2011;57(2):67-81
Functional dyspepsia (FD) is defined as the presence of symptoms thought to originate in the gastroduodenal area, in the absence of any organic, systemic, or metabolic disease that is likely to explain the symptoms. Based on the available evidence and consensus opinion, thirteen consensus statements for the treatment of FD were developed using the modified Delphi approach. Proton pump inhibitor, prokinetics, and histamine 2 receptor antagonists are effective for the treatment of FD. Mucosal protecting agents, fundus relaxant, and drugs for visceral hypersensitivity can improve symptoms in FD. Antacids and antidepressants may help improving symptoms in FD. Comparing endoscopy with 'test and treat' of Helicobacter pylori, endoscopy may be more effective initial strategy for managing patients with FD in Korea given high incidence of gastric cancer and low cost of endoscopy. Helicobacter pylori eradication can be one of the therapeutic options for patients with FD. Psychotherapy is effective for those who have severe symptoms and refractoriness. Further studies are strongly needed to develop better treatment strategies for Korean patients with FD.
Antacids/therapeutic use
;
Anti-Ulcer Agents/therapeutic use
;
Antidepressive Agents/therapeutic use
;
Dyspepsia/diet therapy/*therapy
;
Gastroscopy
;
Helicobacter Infections/drug therapy
;
Helicobacter pylori
;
Histamine H2 Antagonists/therapeutic use
;
Humans
;
Proton Pump Inhibitors/therapeutic use
;
Psychotherapy
;
Serotonin 5-HT3 Receptor Antagonists/therapeutic use
;
Vasoconstrictor Agents/therapeutic use
8.Wide-Awake Primary Flexor Tendon Repair, Tenolysis, and Tendon Transfer.
Clinics in Orthopedic Surgery 2015;7(3):275-281
Tendon surgery is unique because it should ensure tendon gliding after surgery. Tendon surgery now can be performed under local anesthesia without tourniquet, by injecting epinephrine mixed with lidocaine, to achieve vasoconstriction in the area of surgery. This method allows the tendon to move actively during surgery to test tendon function intraoperatively and to ensure the tendon is properly repaired before leaving the operating table. I applied this method to primary flexor tendon repair in zone 1 or 2, tenolysis, and tendon transfer, and found this approach makes tendon surgery easier and more reliable. This article describes the method that I have used for tendon surgery.
Anesthetics, Local/administration & dosage/therapeutic use
;
Epinephrine/administration & dosage/therapeutic use
;
Humans
;
Range of Motion, Articular
;
Suture Techniques
;
*Tendon Injuries/rehabilitation/surgery
;
Tendon Transfer/*methods
;
Tendons/*surgery
;
Vasoconstrictor Agents/administration & dosage/therapeutic use
9.Comparison of Terlipressin and Octreotide with Variceal Ligation for Controlling Acute Esophageal Variceal Bleeding: a Randomized Prospective Study.
Sung Bum CHO ; Kang Jin PARK ; Jung Soo LEE ; Wan Sik LEE ; Chang Hwan PARK ; Young Eun JOO ; Hyun Soo KIM ; Sung Kyu CHOI ; Jong Sun REW ; Sei Jong KIM
The Korean Journal of Hepatology 2006;12(3):385-393
BACKGROUND/AIMS: Terlipressin and octreotide had been used to control acute variceal bleeding and to prevent early rebleeding after endoscopic hemostasis. We compared the efficacy and safety of terlipressin and octreotide combined with endoscopic variceal ligation (EVL) for the treatment of acute esophageal variceal bleeding and we evaluated their clinical significance as related to rebleeding. METHODS: The eighty eight cirrhotic patients were randomized to the terlipressin group (n=43; 2 mg i.v. initially and 1 mg i.v. at every 4 hours for 3 days) or the octreotide group (n=45; continuous infusion of 25 microgram/h for 5 days) combined with EVL for the treatment of acute esophageal variceal bleeding. RESULTS: The initial hemostasis rates were 98% (42/43 cases) in the terlipressin group and 96% (43/45 cases) in the octreotide group. The 5-day and 42-day rebleeding rates were 12% (5/43 cases) and 28% (12/43 cases), respectively, in the terlipressin group and 9% (4/45 cases) and 24% (11/45 cases), respectively, in the octreotide group. No significant difference was demonstrated between the terlipressin and octreotide groups. The mortality at 42 days was similar in both group, but a high mortality rate (48%) was shown to be related to 42-day rebleeding. The risk factors related to 42-day rebleeding were Child-Pugh class C (aOR=30.2, 95% CI=7.7-117.9), ascites above grade II (aOR=6.6, 95% CI=2.2-19.2) and advanced hepatocellular carcinoma (aOR=4.6, 95% CI=1.1-18.9). CONCLUSIONS: Comparing terlipressin and octreotide combined with EVL showed them to be equally safe and effective therapeutic agents in patients with acute esophageal variceal bleeding. The high risk factors related to early rebleeding were poor liver function and advanced hepatocellular carcinoma.
Acute Disease
;
Aged
;
Esophageal and Gastric Varices/drug therapy/surgery/*therapy
;
Female
;
Gastrointestinal Hemorrhage/drug therapy/surgery/*therapy
;
Humans
;
Liver Cirrhosis/drug therapy/surgery/*therapy
;
Lysine Vasopressin/*analogs & derivatives/therapeutic use
;
Male
;
Middle Aged
;
Octreotide/*therapeutic use
;
Vasoconstrictor Agents/*therapeutic use
10.Comparison of two vasopressor protocols for preventing hypotension post-spinal anesthesia during cesarean section: a randomized controlled trial.
Qian-Qian FAN ; Yong-Hui WANG ; Jing-Wen FU ; Hai-Long DONG ; Man-Ping YANG ; Duo-Duo LIU ; Xiao-Fan JIANG ; Zhi-Xin WU ; Li-Ze XIONG ; Zhi-Hong LU
Chinese Medical Journal 2021;134(7):792-799
BACKGROUND:
Norepinephrine infusion decreases hypotension after spinal anesthesia during cesarean section. This study aimed to compare the efficacy of norepinephrine infusion and ephedrine bolus against post-spinal hypotension in parturients.
METHODS:
In this double-blinded, randomized controlled clinical trial, parturients scheduled for elective cesarean section were randomly allocated to receive norepinephrine infusion (0.05 μg·kg-1·min-1) just before spinal anesthesia continuing for 30 min or ephedrine bolus (0.15 mg/kg) just before spinal anesthesia. A rescue bolus (5 μg norepinephrine for the norepinephrine group, and 5 mg ephedrine for the ephedrine group) was administered whenever hypotension occurred. Our primary outcome was the incidence of hypotension within 30 min of spinal anesthesia administration. Secondary outcomes included maternal and neonatal outcomes 30 min after spinal block, and neonatal cerebral oxygenation 10 min after birth.
RESULTS:
In total, 190 patients were enrolled; of these patients, 177 were included in the final analysis. Fewer patients suffered hypotension in the norepinephrine group than in the ephedrine group (29.5% vs. 44.9%, odds ratio [OR]: 0.51, 95% confidence interval [CI]: 0.28-0.95, P = 0.034). Moreover, the tachycardia frequency was lower in the norepinephrine group than in the ephedrine group (OR: 0.22, 95% CI: 0.11-0.44, P < 0.001), and patients suffered less nausea and vomiting (OR: 0.28, 95% CI: 0.11-0.70, P = 0.004). There was no difference in Apgar scores and umbilical arterial blood gas analysis between the two groups. However, neonatal cerebral regional saturations were significantly higher after birth in the norepinephrine group than in the ephedrine group (mean difference: 2.0%, 95% CI: 0.55%-3.45%, P = 0.008).
CONCLUSION:
In patients undergoing elective cesarean section with spinal anesthesia, norepinephrine infusion compared to ephedrine bolus resulted in less hypotension and tachycardia, and exhibited potential neonatal benefits.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT02542748; https://clinicaltrials.gov/ct2/show/record/NCT02542748.
Anesthesia, Spinal/adverse effects*
;
Cesarean Section/adverse effects*
;
Double-Blind Method
;
Female
;
Humans
;
Hypotension/prevention & control*
;
Infant, Newborn
;
Phenylephrine
;
Pregnancy
;
Randomized Controlled Trials as Topic
;
Vasoconstrictor Agents/therapeutic use*